2-Hydroxyethyl propan-2-ylcarbamate | 62788-99-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Hydroxyethyl propan-2-ylcarbamate
• 英文别名: 2-hydroxyethyl N-propan-2-ylcarbamate
• CAS: 62788-99-2
• 化学式: C₆H₁₃NO₃
• 分子量: 147.17
• InChiKey: LHGHPKFQVWZZDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor
  申请人：NANJING SANHOME PHARMACEUTICAL CO., LTD

  公开号：US10093656B2

  公开（公告）日：2018-10-09

  Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.

  公开了一种作为突变选择性表皮生长因子受体抑制剂的融合环或三环芳基嘧啶化合物。具体地说，公开了一种由式（I）代表并用作表皮生长因子受体抑制剂的化合物或其药学上可接受的盐。
• FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR
  申请人：GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD.

  公开号：EP3290419B1

  公开（公告）日：2019-08-07
• DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY
  申请人：XRad Therapeutics, Inc.

  公开号：EP3784671A1

  公开（公告）日：2021-03-03
• Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor
  申请人：GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

  公开号：US20180072704A1

  公开（公告）日：2018-03-15

  Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.
• [EN] DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY<br/>[FR] INHIBITEURS DOUBLES D'ATM ET D'ADN-PK POUR UNE UTILISATION EN THÉRAPIE ANTITUMORALE
  申请人：XRAD THERAPEUTICS INC

  公开号：WO2019201283A1

  公开（公告）日：2019-10-24

  Provided herein are compounds of the Formula (I), (II), and (III), as well as pharmaceutically acceptable salts thereof, wherein the substituents are those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of oncologic diseases.